Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SB010 in Moderate to Severe COPD
DRKS00006087Phase 2Completed
- Sponsor
- Philipps-Universität Marburg
- Start
- Jun 2014
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing SB010 with Placebo (2 arms). Primary endpoints: Safety and tolerability of inhaled SB010, Efficacy of SB010 and 2 more. Started Jun 2014; status: completed.
02
Drugs
SB010
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on DRKS00006087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00006087.